Amgen, Inc. vs Ryanair Holdings plc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Ryanair Holdings plc trades at $60.03 (market cap $29.63B). The key difference: Amgen, Inc. is far larger — about 7.6× Ryanair Holdings plc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | RYAAY | |
|---|---|---|
Market Cap | $224.14B | $29.63B |
Sector | Health | Industrials |
52-Week High | $417.20 | $73.82 |
52-Week Low | $271.18 | $53.24 |
Enterprise Value | $267.45B | $26.61B |
Dividend Yield | 2.43% | 1.51% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →